Class: Antiretroviral Agent, Integrase Inhibitor
Dosage Forms. Tablet: 200 mg; Chewable Tablet: 25 mg; 100 mg
Common FDA Label Indication, Dosing, and Titration.
1. Treatment of HIV-1 infection in combination with other antiretroviral agents: Adults and Children ≥12 y, 400 mg po bid; Children <12 years, weight based
Off-Label Uses. None
MOA. Raltegravir inhibits the catalytic activity of integrase HIV-1 integrase, thus preventing integration of the proviral gene into human DNA.
Drug Characteristics: Raltegravir
Medication Safety Issues: Raltegravir
Drug Interactions: Raltegravir
Adverse Reactions: Raltegravir
Efficacy Monitoring Parameters. HIV viral load, CD4 count, HIV resistance testing.
Toxicity Monitoring Parameters. Liver function tests, bilirubin, CBC, glucose.
Key Patient Counseling Points. Take with or without food. May chew or crush the chewable tablet. Does not prevent transmission of HIV; practice safe sex.
Clinical Pearls. Not recommended for children less than 2 y of age. Recommended as a first-line therapy with tenofovir/emtricitabine in antiretroviral naïve patients.